Canadian CanadaBis Reports C$3.97M Net Revenue In Q3 2024, 26% Decline YoY
Canadian CanadaBis Reports C$3.97M Net Revenue In Q3 2024, 26% Decline YoY
Alberta-based vertically integrated cannabis operator CanadaBis (CVE:CANB) announced the results from their Q3 2024 for the company and its subsidiaries Stigma Pharmaceuticals Inc., Stigma Grow, Stigma Roots, Indicative Collection and Goldstream Cannabis Inc.
總部位於艾伯塔省的大麻製造業垂直一體化運營商CanadaBis(CVE:CANB)宣佈了公司及其子公司Stigma藥品公司，Stigma種植園，Stigma根系植物，Indicative Collection和Goldstream Cannabis Inc. 的2024財年第三季度業績。
Despite showing a decrease of 26% YoY for Q3, the company highlighted the fact that it is its tenth consecutive quarter generating revenue. The positive results come amid a challenging economy for Cannabis in Canada, which pushed the company to seek increased operational efficiency.
儘管第三季度按年計算下降26％，公司強調這是第十個連續營收季度。積極的結果出現在對加拿大大麻經濟挑戰的背景下，這促使公司尋求提高運營效率。
"Canadabis Capital's performance in Q3 2024 was robust, driven by our strategic investments and continuous efforts to optimize our operational efficiencies," said CEO Travis Mcintyre.
"Canadabis Capital在2024財年第三季度的表現強勁，受戰略投資和持續優化運作效率的推動，"首席執行官Travis Mcintyre表示。
Q3 2024 Financial Results Compared To Q3 2023
2024 Q3 財務業績與2023 Q3相比
- Gross Revenue: For the three months ended April 30, 2024, gross revenue was $7.08 million compared to $9.59 million for the same period in 2023, marking a decrease of 26%.
- Net Revenue: Net revenue followed a similar trend, decreasing to $3.97 million from $6.05 million year over year, influenced by both the excise duty adjustments and market dynamics.
- Cost of Sales: Cost of sales saw a slight decline to $1.80 million from $3.35 million, reflecting improved cost management strategies.
- Gross Profit: Gross profit was $2.17 million for the recent quarter, down from $2.70 million in 2023, demonstrating tighter revenue conditions.
- Net Income: Net income for the three months saw a decrease to $109,824, compared to $1.20 million in 2023.
- EBITDA: Adjusted EBITDA decreased to $497,663 from $1.53 million, aligning with the observed reductions in gross profit and net income
- 毛收入：截至2024年4月30日的三個月內，毛收入爲708萬美元，相比之下，2023年同期爲959萬美元，下降了26％。
- 淨收入：淨收入呈相似的趨勢下降，由於消費稅調整和市場動態的影響，從去年同期的605萬美元降至397萬美元。
- 銷售成本：銷售成本略有下降，由去年同期的335萬美元下降到180萬美元，反映了改善的成本管理策略。
- 毛利潤：最近一個季度的毛利潤爲217萬美元，低於2023年的270萬美元，表明更加嚴格的收入條件。
- 淨利潤：最近三個月的淨利潤下降至10.9萬美元，相比之下，2023年爲120萬美元。
- 調整後的EBITDA從153萬美元下降到49.8萬美元，與毛利潤和淨利潤的觀察到的下降相一致。
See also: Canadian Vs. U.S. Cannabis Companies: Who Is Winning The Market Race To Weed Profits?
另請參閱：加拿大與美國的大麻公司：誰在大麻市場的競賽中獲得了勝利？
As for operational highlights, CanadaBis launched Canada's first 60% THC pre-roll. The company reported on significant investment in research and development to enhance its product lineup and manufacturing techniques; and formed a strategic partnership with a Portuguese distribution company to expand in the european market.
至於運營亮點，CanadaBis推出了加拿大首個60％ THC預捲菸。該公司報告了在研究和開發方面的重大投資，以增強其產品陣容和製造技術。此外還與葡萄牙的分銷公司合作，以擴大在歐洲市場的影響力。
CanadaBis Stock Action
CanadaBis的股票行情
CanadaBis Stock is trading at $0.0650 at the moment of this writing, down 13.3% from Tuesday.
此時CanadaBis的股票價格爲0.0650美元，比星期二下降了13.3％。